• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Neuropace Inc.

    3/4/25 5:29:00 PM ET
    $NPCE
    Medical/Dental Instruments
    Health Care
    Get the next $NPCE alert in real time by email
    S-8 1 d854264ds8.htm S-8 S-8

    As filed with the U.S. Securities and Exchange Commission on March 4, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    NeuroPace, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   22-3550230

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    455 N. Bernardo Avenue

    Mountain View, California 94043

    (650) 237-2700

    (Address of Principal Executive Offices) (Zip Code)

    NeuroPace, Inc. 2021 Equity Incentive Plan

    NeuroPace, Inc. 2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    Joel Becker

    Chief Executive Officer

    NeuroPace, Inc.

    455 N. Bernardo Avenue

    Mountain View, California 94043

    (650) 237-2700

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Mark B. Weeks

    Jaime L. Chase

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed by NeuroPace, Inc. (the “Registrant”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) an additional 1,507,251 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan (the “2021 Plan”) and (ii) an additional 301,450 shares of Common Stock to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “2021 ESPP”). The Registrant previously registered shares of its Common Stock for issuance under the 2021 Plan and 2021 ESPP on Registration Statements on Form S-8 filed with the Commission on April 23, 2021 (File No. 333-255453), March 11, 2022 (File No. 333-263462), March 2, 2023 (File No. 333-270246) and March  5, 2024 (File No. 333-277683) (collectively, the “Prior Registration Statements”).

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2021 Plan and 2021 ESPP, are incorporated herein by reference and made part of this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents By Reference.

    The following documents filed by NeuroPace, Inc. (the “Registrant”) with the Commission (File No. 001-40337) are incorporated by reference into this Registration Statement:

    (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 4, 2025;

    (b) the Registrant’s Current Reports on Form 8-K filed on January  8, 2025, January  28, 2025, February  14, 2025, February  18, 2025 and February 20, 2025; and

    (c) the description of the Registrant’s common stock which is contained in a registration statement on Form 8-A filed on April 14, 2021 under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. The Registrant is not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8.Exhibits.

    The exhibits to this Registration Statement are listed below:

     

              Incorporated by Reference  

    Exhibit
    Number

      

    Description

       Schedule
    Form
         File
    Number
         Exhibit      Filing Date  
      4.1    Amended and Restated Certificate of Incorporation of the Registrant.      8-K        001-40337        3.1        April 26, 2021  
      4.2    Amended and Restated Bylaws of the Registrant.      S-1/A        333-254663        3.4        April 14, 2021  
      5.1*    Opinion of Cooley LLP.            
     23.1*    Consent of Cooley LLP (included in Exhibit 5.1).            
     23.2*    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.            
     24.1*    Power of Attorney (included on the signature page of this Form S-8).            
     99.1    2021 Equity Incentive Plan.      S-1/A        333-254663        10.6        April 14, 2021  
     99.2    2021 Employee Stock Purchase Plan.      S-1/A        333-254663        10.8        April 14, 2021  
    107*    Filing Fee Table            

     

    *

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on this 4th day of March 2025.

     

    NeuroPace, Inc.
    By:  

    /s/ Joel Becker

      Joel Becker
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joel Becker and Rebecca Kuhn, and each of them, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her in any and all capacities, to sign the Registration Statement on Form S-8 of NeuroPace, Inc., and any or all amendments (including post-effective amendments thereto), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Joel Becker

    Joel Becker

      

    Director and Chief Executive Officer

    (Principal Executive Officer)

      March 4, 2025

    /s/ Rebecca Kuhn

    Rebecca Kuhn

      

    Chief Financial Officer and Vice President,

    Finance and Administration (Principal Financial
    Officer and Principal Accounting Officer)

      March 4, 2025

    /s/ Lisa Andrade

    Lisa Andrade

       Director   March 4, 2025

    /s/ Frank Fischer

    Frank Fischer

       Director   March 4, 2025

    /s/ Uri Geiger

    Uri Geiger

       Director   March 4, 2025

    /s/ Scott Huennekens

    Scott Huennekens

       Director   March 4, 2025

    /s/ Rakhi Kumar

    Rakhi Kumar

       Director   March 4, 2025

    /s/ Joseph S. Lacob

    Joseph S. Lacob

       Director   March 4, 2025

    /s/ Renee Ryan

    Renee Ryan

       Director   March 4, 2025
    Get the next $NPCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NPCE

    DatePrice TargetRatingAnalyst
    5/28/2025$18.00Buy
    H.C. Wainwright
    1/21/2025$17.00Buy
    UBS
    3/14/2024$16.00 → $20.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$22.00Outperform
    Leerink Partners
    11/10/2023$11.00Overweight
    Cantor Fitzgerald
    8/24/2023$5.00 → $6.00Underweight → Equal-Weight
    Morgan Stanley
    2/22/2023$10.00Buy
    Lake Street
    4/6/2022$13.00Outperform
    Wolfe Research
    More analyst ratings

    $NPCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 1,126 shares, decreasing direct ownership by 1% to 105,338 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF FINANCIAL OFFICER Kuhn Rebecca covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.27% to 132,950 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:09 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • CHIEF MEDICAL OFFICER Morrell Martha covered exercise/tax liability with 357 shares, decreasing direct ownership by 0.41% to 87,281 units (SEC Form 4)

      4 - NeuroPace Inc (0001528287) (Issuer)

      5/29/25 7:10:06 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Financials

    Live finance-specific insights

    See more

    $NPCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $NPCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

      -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor

      5/27/25 8:00:00 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Reports First Quarter 2025 Financial Results

      -- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. Recent Highlights Revenue g

      5/13/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Provides Update on Tariff Status

      -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside th

      4/14/25 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on NeuroPace with a new price target

      H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00

      5/28/25 9:08:28 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on NeuroPace with a new price target

      UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00

      1/21/25 8:23:18 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously

      3/14/24 8:11:10 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 6:30:12 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      11/14/24 3:36:16 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuropace Inc.

      SC 13G/A - NeuroPace Inc (0001528287) (Subject)

      10/3/24 4:46:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    Leadership Updates

    Live Leadership Updates

    See more
    • NeuroPace Continues to Strengthen Management Team

      MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments

      10/16/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Strengthens Management Team with Two Key Appointments

      Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma

      9/4/24 4:05:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • NeuroPace Announces CEO Transition

      NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace'

      6/28/23 4:03:00 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care

    $NPCE
    SEC Filings

    See more
    • Neuropace Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - NeuroPace Inc (0001528287) (Filer)

      5/27/25 8:09:45 AM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Neuropace Inc.

      SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)

      5/15/25 8:15:55 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Neuropace Inc.

      10-Q - NeuroPace Inc (0001528287) (Filer)

      5/13/25 5:15:48 PM ET
      $NPCE
      Medical/Dental Instruments
      Health Care